Baloxavir marboxil

(Xofluza)

Baloxavir marboxil

Drug updated on 11/15/2023

Dosage FormTablet (oral; 40 mg, 80 mg), Oral suspension (oral; 40 mg/20 mL)
Drug ClassInfluenza virus polymerase acidic endonuclease inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications.
  • For post-exposure prophylaxis of influenza in patients 12 years of age and older following contact with an individual who has influenza.

Product Monograph / Prescribing Information

Document TitleYearSource
Xofluza (baloxavir marboxil) Prescribing Information.2023Genentech USA, Inc., South San Francisco, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis. 2023Journal of infection and chemotherapy
Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. 2022Expert Review of Anti-infective Therapy
Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials.2021Journal of Microbiology, Immunology and Infection
Comparison of antiviral agents for seasonal influenza outcomes in healthy adults and children. 2021JAMA Network Open
Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.2021Expert Review of Clinical Pharmacology
Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.2021Expert Review of Clinical Pharmacology
Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: a systematic review and meta-analysis of randomized controlled trials. 2021Journal of Microbiology, Immunology and Infection
Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients – a Bayesian network meta-analysis.2021Current Medical Research and Opinion
A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.2019Current Medical Research and Opinion